Luscan-Lumish Syndrome: Comprehensive Disease Characteristics Report

Disease Name: Luscan-Lumish Syndrome (LLS) MONDO ID: MONDO:0014916 OMIM (phenotype): #616831 · OMIM (gene): 612778 · Orphanet: ORPHA:457485 Category: Genetic (autosomal dominant overgrowth + neurodevelopmental disorder) Causal Gene: SETD2* (HGNC:18420; NCBI Gene 29072; UniProt Q9BYW2; chromosome 3p21.31)

Summary

Luscan-Lumish syndrome (LLS) is an ultra-rare, autosomal-dominant overgrowth and neurodevelopmental disorder caused by heterozygous, near-universally de novo loss-of-function (LoF) variants in SETD2, the sole somatic histone H3 lysine-36 trimethyltransferase (H3K36me3). First delineated by Lumish and colleagues in 2015 in a girl with autism, intellectual disability, seizures, Chiari I malformation, and macrocephaly carrying a de novo frameshift variant (c.2028delT, p.P677LfsX19), the condition has since been reported in approximately 50 patients worldwide. The core clinical picture combines postnatal overgrowth — macrocephaly (near-universal), tall/advanced stature, and obesity (~50%) — with a highly penetrant neurodevelopmental and behavioral phenotype: intellectual disability (~83%), autism spectrum disorder (~89%), and behavioral difficulties (~100%), often with aggressive outbursts (~83%), speech and motor delay, and advanced carpal (bone) ossification. LLS is classified within the "Sotos-like" family of epigenetic overgrowth syndromes.

The molecular basis is dual. SETD2 is a "chromatocytoskeletal" dual-function methyltransferase: it writes H3K36me3 — essential for transcriptional fidelity (suppression of cryptic transcription), splicing, DNA repair, and genomic stability — and it also methylates α-tubulin at Lys40 (α-TubK40me3) and actin, linking it to microtubule/cytoskeletal function. Haploinsufficiency therefore simultaneously perturbs chromatin regulation and cytoskeletal dynamics. Model-organism work directly ties both arms to the phenotype: the H2A.z–Setd2–H3K36me3 axis drives embryonic cortical neurogenesis (via Nkx2-4), and α-TubK40me3 is required for neuronal polarization and migration in the developing cortex, as well as for mitotic-spindle integrity.

Diagnosis is molecular — trio whole-exome or whole-genome sequencing, or overgrowth/intellectual-disability multigene panels — now reinforced by a distinctive SETD2 DNA-methylation episignature (EpiSign) that supports diagnosis and reclassifies variants of uncertain significance. Importantly, a genotype–phenotype dichotomy exists at the same locus: recurrent de novo missense variants at codon 1740 produce clinically distinct, more severe, growth-restricted disorders — Rabin-Pappas syndrome (RAPAS, p.Arg1740Trp; MIM 620155) and autosomal-dominant intellectual developmental disorder 70 (MRD70, p.Arg1740Gln) — implying a non-LoF (e.g., gain-of-function or altered epigenetic-regulation) mechanism rather than simple haploinsufficiency. No disease-specific or curative therapy exists; management is entirely supportive and multidisciplinary.

1. Disease Information

LLS is a monogenic overgrowth-with-intellectual-disability syndrome in the "Sotos-like" group. It is characterized by "postnatal overgrowth, macrocephaly, obesity, speech delay, and advanced carpal ossification" together with a strongly penetrant neurodevelopmental/behavioral profile (PMID: 31643139).

Key identifiers: - OMIM (phenotype): #616831 (Luscan-Lumish syndrome) - OMIM (gene): 612778 (SETD2) - Orphanet: ORPHA:457485 - MONDO: MONDO:0014916 - MeSH / ICD: No dedicated MeSH heading or specific ICD-10 code; captured under broad codes for congenital malformation syndromes / intellectual disability. ICD-11 would map to a rare-syndrome/developmental-anomaly category. - HGNC: HGNC:18420 (SETD2*)

Synonyms / alternative names: SETD2-related overgrowth syndrome; SETD2-related disorder; intellectual disability, autosomal dominant, with overgrowth (historical descriptions). Note that "SETD2-related disorders" is an umbrella now spanning three nosologically distinct entities: LLS, MRD70, and RAPAS (PMID: 37372360).

Source of information: Aggregated disease-level knowledge from published case reports/series (~50 patients) and mechanistic/model-organism studies — not from a large EHR cohort.

2. Etiology

Primary cause (genetic). LLS is caused by heterozygous, intragenic loss-of-function variants in SETD2. Constitutional SETD2 mutations are "intragenic loss-of-function variants with truncating (69%) and missense (31%) mutations" (PMID: 31643139). The founding case carried a de novo frameshift: "a de novo c.2028delT (P677LfsX19) mutation in the SET domain-containing protein 2 (SETD2) gene, predicted to be gene-damaging" (PMID: 26084711).

Genetic risk factors. The causal event is the SETD2 LoF variant itself, arising de novo; there are no known susceptibility loci or modifier genes established for LLS. Large 3p21.31 deletions encompassing SETD2 can reproduce part of the phenotype (PMID: 27385966).

Environmental risk factors / protective factors / gene–environment interactions. None established. As a de novo dominant Mendelian disorder, LLS has no recognized environmental, lifestyle, or infectious contribution, and no protective alleles or GxE interactions have been reported. Advanced paternal age is a general (non-specific) consideration for de novo single-nucleotide variants but is not documented specifically for LLS.

3. Phenotypes

Per-phenotype frequencies derive chiefly from the Marzin (2019) cohort (n=13): "neurodevelopmental disorders are common such as intellectual disability (83%), autism spectrum disorders (89%), and behavioral difficulties (100%) with aggressive outbursts (83%). A variety of features such as joint hypermobility (29%), hirsutism (33%), and naevi (50%) were also reported" (PMID: 31643139).

Phenotype Type Frequency Onset Suggested HPO
Macrocephaly physical ~all postnatal/childhood HP:0000256
Behavioral difficulties behavioral ~100% childhood HP:0000708
Autism spectrum disorder behavioral ~89% childhood HP:0000729
Intellectual disability cognitive ~83% childhood HP:0001249
Aggressive outbursts behavioral ~83% childhood HP:0000718
Tall/advanced stature physical ~50% postnatal HP:0000098
Obesity physical ~50% childhood HP:0001513
Naevi physical sign ~50% variable HP:0001054
Hirsutism physical sign ~33% variable HP:0001007
Joint hypermobility physical ~29% childhood HP:0001382
Speech delay developmental common early childhood HP:0000750
Motor delay developmental common early childhood HP:0001270
Advanced carpal ossification radiographic common childhood HP:0011834
Chiari I malformation structural reported subset congenital HP:0002344
Seizures neurological reported subset childhood HP:0001250
Facial dysmorphism physical reported congenital HP:0001999
Recurrent otitis media clinical reported childhood HP:0000403
Bilateral condylar hyperplasia physical (rare) single report adolescence —

Severity/progression: Variable expressivity, ranging from a mild adult overgrowth presentation "without neurological symptoms" (PMID: 33248444) to classic ID/ASD/overgrowth. Core neurodevelopmental features are generally stable (non-progressive) but lifelong. A rare/unusual manifestation, bilateral condylar hyperplasia, has been reported as part of the expanding phenotype (PMID: 40892041).

Quality-of-life impact: Driven mainly by ID, ASD, and behavioral difficulties (impact on communication, education, independence, and family/caregiver burden). Formal QoL instrument data (EQ-5D/SF-36/PROMIS) are not published for LLS.

4. Genetic / Molecular Information

Genotype–phenotype dichotomy at codon 1740: Rabin (2020) identified 15 individuals with de novo codon-1740 variants — p.Arg1740Trp (n=12) → RAPAS (microcephaly, profound ID, multi-organ anomalies; MIM 620155) and p.Arg1740Gln (n=3) → MRD70 (moderate-severe ID). "The phenotype of Group 1 includes microcephaly, profound intellectual disability, congenital anomalies affecting several organ systems, and similar facial features," and "the clinical features seen in individuals with variants affecting codon 1740 are more severe suggesting an alternative mechanism, such as gain of function, effects on epigenetic regulation, or posttranslational" modification (PMID: 32710489).

5. Environmental Information

No environmental, lifestyle, or infectious factors are known to cause or trigger LLS. It is a monogenic de novo dominant disorder. Obesity, when present, is a phenotypic feature partly amenable to lifestyle/nutritional management rather than an etiologic exposure (PMID: 29681085). No infectious agents apply.

6. Mechanism / Pathophysiology

Central node — SETD2 dual enzymatic activity. SETD2 "is a dual-function methyltransferase for histones and microtubules and plays an important role for transcriptional regulation, genomic stability, and cytoskeletal functions" (PMID: 32710489); it has "chromatocytoskeletal activity, methylating both histones and microtubules" (PMID: 32620673).

Chromatin arm (H3K36me3). As the sole somatic H3K36me3 writer, SETD2 loss reduces transcriptional fidelity (allowing cryptic transcription), impairs co-transcriptional splicing, and compromises DNA repair and genomic stability. In the brain, the H2A.z–Setd2–H3K36me3 axis drives neurogenesis: "H2A.z regulates embryonic neurogenesis by targeting Nkx2-4 through interaction with Setd2, thereby promoting H3K36me3 modification to activate the transcription of Nkx2-4" (PMID: 29294103).

Cytoskeletal arm (α-TubK40me3). SETD2 methylates α-tubulin at Lys40; this mark is enriched in mouse cortex at E14–E16 and is required for neuronal migration: "Knockdown of α-tubulin methyltransferase SETD2 at E14 leads to the defects in neuronal migration, which could be restored by overexpressing either a cytoplasm-localized SETD2 truncation or α-TubK40me3-mimicking mutant" (PMID: 34226540). Loss also degrades spindle integrity: "SETD2 is a dual-function methyltransferase important for methylation of histone H3 at lysine 36 and α-tubulin in spindle microtubules" (PMID: 41827754), producing chromatin bridges, micronuclei, and aneuploidy. The α-TubK40me3 regulatory triad comprises writer SETD2, reader PBRM1, and eraser KDM4A (PMID: 41171906); a Drosophila Set2 E741Q model confirms spindle defects (PMID: 38290049).

Candidate overgrowth mechanism. In one LLS case, patient cells "showed enhanced tyrosine phosphorylation and transcriptional activity of signal transducer and activator of transcription 5b (STAT5b) and increased IGF-1 expression induced by GH" (PMID: 33248444), implicating a GH→STAT5b→IGF-1 axis in postnatal overgrowth (single case; not yet generalized).

Suggested ontology terms: - GO (BP): histone H3-K36 trimethylation (GO:0010452); DNA repair (GO:0006281); microtubule cytoskeleton organization (GO:0000226); mitotic spindle organization (GO:0007052); neuron migration (GO:0001764); regulation of transcription elongation. - GO (CC): nucleus (GO:0005634); chromatin (GO:0000785); microtubule (GO:0005874); mitotic spindle (GO:0072686). - CL: neuron (CL:0000540); cortical projection neuron; radial glial/neural progenitor cell (CL:0000047). - CHEBI: S-adenosyl-L-methionine (CHEBI:15414, methyl donor).

7. Anatomical Structures Affected

8. Temporal Development

9. Inheritance and Population

10. Diagnostics

11. Outcome / Prognosis

12. Treatment

There is no disease-specific or curative therapy; management is supportive and multidisciplinary.

13. Prevention

14. Other Species / Natural Disease

15. Model Organisms

Model System Key finding Relevance to LLS PMID
Mouse constitutive KO Mammalian Embryonic lethal (vascular/mesodermal defects) Confirms essentiality; requires conditional/het models (established)
Mouse H2A.z brain-specific deletion Mammalian H2A.z–Setd2–H3K36me3 → Nkx2-4 drives neurogenesis; deletion → cortical neurogenesis defects, abnormal dendrites, learning/memory deficits Models neurodevelopmental arm 29294103
Mouse in-utero SETD2 knockdown (E14) Mammalian Neuronal migration defects; rescued by cytoplasmic SETD2 / α-TubK40me3 mimic / Taxol Models cytoskeletal (migration) arm 34226540
Zebrafish setd2 Vertebrate Sole H3K36me3 writer on transcribed genes; essential in development Validates enzyme uniqueness 33088589
Drosophila Set2 E741Q Invertebrate ↓ H3K36me3 + mitotic-spindle defects Models spindle/genomic-stability arm 38290049

Model characteristics / limitations: Constitutive knockouts are embryonic lethal and cannot model the heterozygous adult phenotype; most models isolate one mechanistic arm (chromatin or cytoskeleton); behavioral and overgrowth features are not yet co-recapitulated in a single dose-accurate mammalian model. Resources: MGI (Setd2), ZFIN (setd2), FlyBase (Set2).

Mechanistic Model / Interpretation

        Heterozygous de novo SETD2 loss-of-function variant
                 (truncating ~69% / missense ~31%)
                              |
                     ~50% reduction in SETD2 dosage
                              |
        ┌─────────────────────┴──────────────────────┐
        │                                             │
   NUCLEAR / CHROMATIN ARM                    CYTOSKELETAL ARM
   ↓ H3K36me3                                 ↓ α-tubulin K40me3
   • transcription fidelity ↓                 • neuronal polarization ↓
   • cryptic transcription ↑                  • neuronal MIGRATION ↓
   • splicing dysregulation                   • mitotic spindle integrity ↓
   • DNA repair / genomic stability ↓         • aneuploidy / micronuclei ↑
        │                                             │
        │  H2A.z–Setd2–H3K36me3 → Nkx2-4              │  (writer SETD2 /
        │  → cortical neurogenesis                    │   reader PBRM1 /
        │                                             │   eraser KDM4A)
        └─────────────────────┬──────────────────────┘
                              |
   Impaired cortical neurodevelopment + dysregulated growth signaling
        (candidate GH → STAT5b → IGF-1 axis in some patients)
                              |
   ┌──────────────────────────┴───────────────────────────┐
   │ NEURODEVELOPMENTAL: ID (~83%), ASD (~89%),            │
   │   behavior (~100%), speech/motor delay, seizures      │
   │ OVERGROWTH: macrocephaly (~all), tall stature/         │
   │   obesity (~50%), advanced carpal ossification        │
   └───────────────────────────────────────────────────────┘

Upstream → downstream logic: The SETD2 LoF variant is the single upstream trigger. Its two enzymatic outputs (H3K36me3 and α-TubK40me3) act as parallel intermediate nodes. The chromatin arm predominantly explains transcriptional/growth dysregulation and neurogenesis defects; the cytoskeletal arm explains neuronal migration and mitotic phenotypes. Both converge on the developing cerebral cortex, yielding the combined overgrowth-plus-neurodevelopmental picture. The codon-1740 growth-restricted disorders (RAPAS/MRD70) at the same locus arise via a distinct (non-LoF) mechanism, showing that dosage and mechanism dictate divergent outcomes.

Evidence Base

PMID Title (abbrev.) Evidence type Supports section(s)
26084711 SETD2 mutation in a child with autism, ID, epilepsy (Lumish 2015) Human clinical (first case) 1, 2, 4
31643139 SETD2-related overgrowth: four new patients + review (Marzin 2019) Human clinical (cohort n=13) 1–4, 10
32710489 Genotype-phenotype at codon 1740 of SETD2 (Rabin 2020) Human clinical + mechanism 4, 6
40104911 Abnormal DNA methylation → syndromic multiple-tumor phenotype Human clinical + epigenetics 1, 4, 9, 10, 11
33248444 LLS case: enhanced GH signaling Human clinical + in vitro 3, 6, 9
37372360 Clinical heterogeneity / three distinct entities Human clinical 1, 4
33766796 Mutation pattern & genotype-phenotype of SETD2 (Chen 2021) Human clinical (curation) 9
29681085 Two novel cases expanding the phenotype Human clinical 12
27385966 3p21.31 interstitial deletion Human clinical (CNV) 4, 10
40282429 Macrocephaly/ASD gene-panel cohort Human clinical 10
40892041 Bilateral condylar hyperplasia in LLS Human clinical (case) 3
29294103 H2A.z deletion → cortical neurogenesis defects Model organism (mouse) 6, 15
33088589 Setd2 sole H3K36me3 writer (zebrafish) Model organism 6, 14, 15
34226540 α-TubK40me3 required for neuronal migration Model organism (mouse) 6, 15
32620673 Chromatocytoskeletal co-regulation by methylation Review/mechanism 6
41827754 SETD2 inhibition → genomic instability In vitro/mechanism 6
41171906 KDM4A is the α-tubulin demethylase In vitro/mechanism 6
38290049 Drosophila Set2 E741Q → spindle defects Model organism 6, 14, 15
40948406 SETD2 tumor suppression (KRAS model) Model organism/mechanism 11
40755378 Setd2 + Kras → JMML, MEK-inhibitor sensitivity Model organism 11
41654133 SETD2 L1609P (leukemia) disrupts activity In vitro/structural 11
37921122 Cellular/molecular functions of SETD2 in CNS Review 6

Limitations and Knowledge Gaps

  1. Small sample size. All clinical conclusions rest on ~50 reported patients (largest single cohort n=13); frequency estimates carry wide confidence intervals and possible ascertainment bias toward severe cases.
  2. No natural-history or registry data. Adult trajectories, life expectancy, and validated quality-of-life metrics are undocumented.
  3. Tumor risk unresolved. SETD2 is a tumor suppressor and a constitutional multi-tumor case exists, but LLS-cohort cancer risk and the value of surveillance are unknown.
  4. Mechanistic attribution. The relative contribution of the chromatin (H3K36me3) versus cytoskeletal (α-TubK40me3) arm to specific human phenotypes has not been dissected in patients.
  5. Intra-LLS genotype–phenotype. Beyond the codon-1740 dichotomy, predictors of severity within LLS (truncation position, residual protein) are unestablished.
  6. No dose-accurate mammalian LLS model. Constitutive KO is lethal; a heterozygous/knock-in model co-recapitulating overgrowth and behavior is lacking.
  7. Overgrowth driver. The GH/STAT5b/IGF-1 finding is from a single case and not generalized.

Proposed Follow-up Experiments / Actions

  1. Establish an international LLS registry to aggregate genotype, phenotype frequencies, growth trajectories, tumor events, and QoL — powering robust penetrance/expressivity and prognosis estimates.
  2. Generate a dose-accurate mouse model (Setd2 heterozygous LoF or patient-specific knock-in) and phenotype for macrocephaly, cortical lamination, dendritic morphology, and behavior.
  3. Refine and standardize the SETD2 EpiSign episignature for VUS reclassification and test whether episignature features distinguish LLS from RAPAS/MRD70 or correlate with severity.
  4. Prospective tumor-surveillance pilot in constitutional SETD2-variant carriers to quantify malignancy risk and evaluate whether imaging/biochemical screening is justified.
  5. Dissect the two mechanistic arms using separation-of-function alleles in patient iPSC-derived cortical organoids/neurons to map which clinical features track with each activity.
  6. Interrogate the GH/STAT5b/IGF-1 axis across multiple patients (serum IGF-1; GH-stimulated STAT5b phosphorylation) to test generalizability and druggability of the overgrowth driver.
  7. Systematic genotype–phenotype meta-analysis of all published SETD2 variants (LLS vs. MRD70 vs. RAPAS) to build a mechanism-aware variant-interpretation framework.

Consensus Answer

Luscan-Lumish syndrome (MONDO:0014916; OMIM #616831) is an ultra-rare, autosomal-dominant, near-universally de novo overgrowth and neurodevelopmental disorder caused by heterozygous loss-of-function variants in SETD2, the sole somatic H3K36 trimethyltransferase. SETD2 haploinsufficiency reduces two methyl marks — histone H3K36me3 (transcriptional fidelity, splicing, DNA repair) and α-tubulin K40me3 (neuronal migration and mitotic-spindle integrity) — producing postnatal overgrowth, macrocephaly, obesity, intellectual disability (~83%), autism (~89%), and behavioral difficulties (~100%). Diagnosis is molecular (trio WES/WGS or overgrowth-ID panels plus a SETD2 DNA-methylation episignature), and management is entirely supportive and multidisciplinary because no disease-specific or curative therapy exists.